학술논문
Estimating excess visual loss from neovascular age-related macular degeneration in the UK during the COVID-19 pandemic: a retrospective clinical audit and simulation model
Document Type
article
Author
Anthony Khawaja; Andrew Lotery; Adnan Tufail; Paul Taylor; Philipp L Müller; Sudeshna Patra; R Khan; E Wilkinson; B Paul; Haralabos Eleftheriadis; Robin Hamilton; S George; V Kumar; R Mukherjee; C Jones; Abraham Olvera-Barrios; Catherine Egan; Roy Schwartz; C Brand; H Palmer; Alasdair Warwick; C Bailey; U Chakravarthy; F Ghanchi; S Mahmood; A Davis; L Downey; G Menon; N Dhingra; R Antcliff; A Lobo; A Patwardhan; T Akerele; Darren S Thomas; Ella Preston; P Lip; S Natha; J Talks
Source
BMJ Open, Vol 12, Iss 4 (2022)
Subject
Language
English
ISSN
2044-6055
Abstract
Objectives To report the reduction in new neovascular age-related macular degeneration (nAMD) referrals during the COVID-19 pandemic and estimate the impact of delayed treatment on visual outcomes at 1 year.Design Retrospective clinical audit and simulation model.Setting Multiple UK National Health Service (NHS) ophthalmology centres.Participants Data on the reduction in new nAMD referrals were obtained from four NHS Trusts comparing April 2020 with April 2019. To estimate the potential impact on 1-year visual outcomes, a stratified bootstrap simulation model was developed drawing on an electronic medical records dataset of 20 825 nAMD eyes from 27 NHS Trusts.Main outcome measures Simulated mean visual acuity and proportions of eyes with vision ≤6/60, ≤6/24 and ≥6/12 at 1 year under four hypothetical scenarios: 0-month, 3-month, 6-month and 9-month treatment delays. Estimated additional number of eyes with vision ≤6/60 at 1 year nationally.Results The number of nAMD referrals dropped on average by 72% (range 65%–87%). Simulated 1-year visual outcomes for 1000 nAMD eyes with a 3-month treatment delay suggested an increase in the proportion of eyes with vision ≤6/60 from 15.5% (13.2%–17.9%) to 23.3% (20.7%–25.9%), and a decrease in the proportion of eyes with vision ≥6/12 (driving vision) from 35.1% (32.1%–38.1%) to 26.4% (23.8%–29.2%). Outcomes worsened incrementally with longer modelled delays. Assuming nAMD referrals are reduced to this level for 1 month nationally, these simulated results suggest an additional 186–365 eyes with vision ≤6/60 at 1 year.Conclusions We report a large decrease in nAMD referrals during the COVID-19 lockdown and provide an important public health message regarding the risk of delayed treatment. As a conservative estimate, a treatment delay of 3 months could lead to a >50% relative increase in the number of eyes with vision ≤6/60 and 25% relative decrease in the number of eyes with driving vision at 1 year.